Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
*** Kip Herriage VRA Update***
Patriot One Tech (PTOTF): The news from yesterday that Pat 1's PATSCAN Weapons Detection System Platform will be installed in the Cincinnati Red's ballpark is being well received...as it should be. This is the beginning of what should be a remarkable year for this VRA 10 Bagger. Here at the VRA we like co's with great mgt teams, sexy products/opportunities and that are flying under the radar. With a market cap of just $200 million, we continue to believe that the shares are cheap and headed much higher. We will be attending the IACP (Intl Assoc of Chief of Police) Conference on Sunday-Tuesday and will report back. The opportunities for Pat 1 in law enforcement are "significant". Keep buying Pat 1.
In hearing from Kip tonight, he also mentions that Donald Trump will be at the IACP this weekend in Chicago.
This event is going to be an amazing platform to show Patriot One and whatever they present in the 40x40 display area with 2 Police Cars.
Can’t wait to hear and see updates from both Kip and Jeff Thomas who will be attending.
Will their be news prior to the weekend? Maybe a hint of what is to come? Time will tell.
From Facebook group
Are they using CMR?
The right direction is straight down?
Samsung to Invest $11 Billion in QD-OLED Panel Production
https://www.anandtech.com/show/14989/samsung-to-invest-11-billion-in-qdoled-panel-production
Sounds like something out of Dr Seuss!
Can someone explain why this verification system is valuable, and who would use it?
Wake me when there's revenue!
I have numerous emails asking for information on financials and when they will be ready, without any response!
Thanks for sharing. She's awesome!
Maybe the kids can get something started; I'm rooting and supporting them! We all need to hold our elected officials accountable!
New Presentation:
https://invobioscience.com/wp-content/uploads/2019/08/INVO-Corp-Presentation-August-2019-FINAL.pdf
Lots of potential here. The method is still relatively unknown!
And that the ladder's financials are current, and the stop sign removed!
Why a business advisory board without any business?
I've been asking about financials for months. No reply!
Never assume the best with a penny stock. Always assume the worst until proven otherwise!
It's sure looking like an extension of the Ken Williams company. Canceling the main project, no reply to emails, elaborate description of grand plans. Just like Ken.
It doesn't say what technology they use. It says detects metalic and non metalic items. Is it CMR?
When asking about financials, I got this reply from Madeline:
Thanks for reaching out! Our support team will look over your message and forward to the most suitable person.
No reply.
Nanosys How does this technology compare to QTMM? Are they close to mass production?
Patriot One, Johnson Controls Partner on Security Platform Integrations
https://www.policemag.com/522790/patriot-one-johnson-controls-partner-on-security-platform-integrations?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+POLICE-All+%28POLICE+Magazine%29&fbclid=IwAR32iRIZMTAS90b_kyD2VzkZE75xoWXxNf1x8n0BelvjQPJuCwhhFB3UHlg
Are we involved in this?
Who are "Fins"?
What's the date on this?
Thanks!
Is Centric Gateway still active? Link goes to a dead website.
INVO Bioscience Reports Record Second Quarter 2019 Financial Results with Revenue Increasing 498%
SARASOTA, Fla., August 14, 2019 -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for its Intravaginal Culture System, INVOcell®, today announced financial results for the second quarter of 2019, ended June 30, 2019.
Q2 2019 Financial Results and Recent Highlights:
?
Revenue for the quarter totaled $658,638 compared to $110,210 in the second quarter of 2018, an increase of 498%. Revenue growth was driven primarily by increased product sales in the U.S. as shipments to Ferring were above expectations outlined in May 2019 as they began to increase their marketing activities.
?
Sequentially, revenue increased approximately 248% for the second quarter compared to $189,432 in the first quarter of 2019.
?
Gross margins for the quarter improved to approximately 92% compared to approximately 85% in the second quarter of 2018.
?
Improved net loss to $(241,552) during the second quarter compared to $(458,570) during the first quarter of 2019.
?
Company ended the quarter in a strong cash position of approximately $2.7 million.
?
Announced the appointment of Pressly Ahammed as the Company’s new Director of International Business Development. Ahammed, together with Chief Operating Officer, Michael Campbell, have advanced business development efforts outside the U.S., including India, China, Latin America and the European Union.
?
On January 14, 2019 the Company closed an exclusive U.S. licensing agreement with Ferring International Center S.A. the parent Company of Ferring Pharmaceuticals U.S. to commercialize the INVOcell™ system for use in the treatment of infertility. As part of the U.S. licensing agreement the Company received a $5 million one-time milestone payment, with the ability to receive an additional $3 million upon obtaining a label enhancement from the U.S. Food and Drug Administration.
Management Discussion
Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, "We are extremely pleased that our second quarter revenues were significantly higher both year-over-year – approximately 498% and sequentially – approximately 248%. Ferring, as our U.S commercialization partner, is exceeding our expectations as they begin to increase both the number of clinics offering the INVOcell and awareness of its attributes. During the quarter we shipped nearly $500,000 in product to them, putting them well above their prorated annual minimum requirements. We are confident in Ferring’s capabilities to expand adoption of the INVOcell procedure and look forward to their continued efforts to grow market share in the years to come.”
Karloff continued, “We are seeing interest from a number of international reproductive specialists to add the INVOcell technology into their respective practices in markets ranging from India, China, Latin America and the European Union. Our business development team is engaging with potential partners who have strong capabilities in these various markets and are staying diligent in our efforts to align ourselves with the best partners that can help bring INVOcell to the millions of couples around the world for which we believe it is an ideal solution to their fertility needs. Domestically, beyond Ferring’s efforts, we are making consistent progress with a number of key opinion leaders in the reproductive industry to establish INVOcell centers throughout the United States with a goal to have multiple centers up and running in 2020.”
“As industry research continues to indicate, the need for affordable and effective reproductive services are highly sought after, both in the U.S. and around the world. We believe INVOcell has an important role to play in this large and expanding global market. We have made tremendous progress over the last twelve months, particularly in the U.S. through our agreement with Ferring, and look to further advance INVOcell’s adoption throughout the rest of the world in the future,” Karloff concluded.
Financial Results
Revenue for the three months ended June 30, 2019, was $658,638 compared to $110,210 for the same three-month period in 2018, an increase of $548,428 or approximately 498%. The increase was primarily the result of increased product sales as Ferring began to increase their marketing activities as well as from recognizing 3.6% of the Ferring seven-year U.S. exclusive licensing & distribution fee.
Gross margin reported for the second quarter ended June 30, 2019 was approximately 92% or $603,356 compared to 85% or $93,500 for the three months ended June 30, 2018. The increase in gross margin was related to the 2019 licensing fee that did not have any cost of sales expenses associated with it. The cost of sales recognized during the second quarter of 2019 were attributed to product shipments to Ferring.
Selling, general and administrative expenses for the three months ended June 30, 2019 were $669,152 as compared to $1,883,946 for the three months ended June 30, 2018, a decrease of $1,214,794 or approximately 64%.
During the three-month period ended June 30, 2019 we incurred $175,756 in interest expense compared to $74,682 in the three-month period ended June 30, 2018. The primary reason for the increase in 2019 was the amortization of discount on the 2018 Convertible Notes Payable in the amount of $163,466 as compared to $56,446 during the same period of 2018.
Net loss of $241,552, or $(0.00) per basic and diluted share for the three months ended June 30, 2019 compared to a net loss of $1,865,128, or $(0.01) per basic and diluted share for the three months ended June 30, 2018.
Messenger chat says EmailMoni not currently available.
Lots of people watching, not many buying an unproven penny stock!
"Various letters back and forth from FCC to Pats legal rep"
Where is this available?
Thanks!
Can you expound on "FCC obstacles/restrictions"?
Thanks!
Have you asked them about it?
So many people, it seems, complain on message boards, without ever contacting the company with their questions!
I wonder what he would say about the state of the current technology and its future?
Come on guys; let's get this technology deployed!
Not until QMC perfects the technology:
"Licensor is obligated to continual to improve and optimize their patented quantum dot solar cell technology and to achieve a peak solar cell conversion efficiency of 15% on or before the 18th month following execution of this agreement. If licensor does not achieve this target performance within this time frame the licensee will deduct and accrue 10% from the total amount of royalties owing until such time the target performance is achieved. Once the target is achieved the accrued royalties will be paid to licensor."
"commercially economic power yield levels"
Source?
What new CEO? Has anyone heard from him?
Financials
I actually received a reply to an email asking about financials:
Thomas:
Your email was forwarded to me…
I have spoken with the company and they are and have been in the process of compiling the financials.
It is a priority for the company but I cannot give you an ETA at this point, but they are in the process and will be released upon completion.
Please feel free to contact us with any questions you have.
From: Thomas Edmonds <mikedmonds@verizon.net>
Date: July 17, 2019 at 3:46:28 PM EDT
To: info@greenstreamfinance.com
Subject: Financials
Dear Green Stream,
I am a potential investor who is waiting on financials before investing.
When do you anticipate publishing them?
Thank you!
Thomas Edmonds
How do you know?
Patscan TMS; new tech?
http://smartctsolutions.com/wp-content/uploads/2018/11/PATSCAN-TMS-Flyer-11x17-v1.0-Final8.3.182.pdf?fbclid=IwAR3u42gzbyEPQmjqHbugAz0CfI0nvg2tgGB_ha_IWtrh99ZAkEpxf73AbzY
http://detect-ors.com/technology/technology-for-security/
https://en.wikipedia.org/wiki/Nuclear_magnetic_resonance